JERUSALEM, May 8 (Reuters) - Teva Pharmaceutical

Industries reported a smaller than expected rise in

first-quarter profit citing higher impairments of tangible

assets, while sales of copycat medicines and its branded drugs

to treat migraines and Huntington's disease rose.

The world's largest generic drugmaker said on Wednesday it

earned 48 cents diluted share excluding one-time items in the

January-March quarter, up from 40 cents per share a year

earlier. Revenue rose 4% to $3.82 billion.

Analysts had forecast earnings of 51 cents per share

ex-items for the Israel-based company on revenue of $3.73

billion, LSEG I/B/E/S data showed.